MOR 202

Drug Profile

MOR 202

Alternative Names: MOR-03087; MOR202; TJ-202

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Preclinical Leukaemia
  • Discontinued Multiple myeloma; Non-small cell lung cancer

Most Recent Events

  • 08 Aug 2018 I-Mab files an IND application with the China National Drug Administration (CNDA) for Multiple myeloma
  • 08 Aug 2018 I-Mab plans to file additional IND applications with the China National Drug Administration and the US FDA to initiate clinical trials including multiple phase II and phase III studies
  • 08 Aug 2018 Discontinued - Preclinical for Non-small cell lung cancer in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top